BusinessWire

Notable Labs Announces Addition of Thomas Bock to Board of Directors

FOSTER CITY, Calif.--(BUSINESS WIRE)--Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced the addition of Dr. Thomas A. Bock to its board of directors.


Bock is a recognized life science leader who built four entrepreneurial organizations that created major impact for both patients and investors, achieving leadership in their fields. He successfully spearheaded new medical paradigms and fast-growing markets such as cancer precision medicine, ultra-rare disorders and cancer prevention.

“We are delighted to welcome Thomas Bock to Notable’s board of directors,” said Laurie Heilmann, Notable CEO. “Thomas’ wealth of experience leading worldwide medical divisions at top-tier pharma organizations such as Novartis, Celgene and Alexion will be of great value to Notable. Thomas developed and commercialized six lifesaving, paradigm-changing blockbuster medicines in cancer, ultra-rare disorders and inflammation. Thomas brings tremendous industry knowledge and experience, which will be instrumental in navigating and supporting Notable’s path forward to becoming a world class leader in drug selection and patient treatment of hematological cancers.”

“I’m excited to join the board at Notable, a company that will redefine how patients, physicians and researchers select the most appropriate drugs for medical therapy and clinical research,” said Bock. “I have spent my career as a champion of bold, healthcare-redefining innovation, technology and medicines — all to achieve more effective, patient-centric treatments. I look forward to helping Notable maximize its impact in this arena, better serving those most in need.”

About Notable

Notable is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers. Notable’s testing platform combines machine learning, automation and high-throughput screening directly on patient samples to predict responses to potential therapies and ultimately determine which therapies will be most effective for specific cancers. Notable’s functional precision medicine platform will advance drug development and enable pharmaceutical companies to get new therapies to patients faster.


Contacts

Jane Byram
SCORR Marketing
512-626-2758
jane@scorrmarketing.com